Cancers by number of trials

JSON

Cancers ordered by how many trial records in the corpus name them. Top 50 of 272 cancers with a value; ties are broken by name. 3,560 of 3,571 trials name at least one cancer (100%).

#	Cancer	Trials	Approved products
1	Non-small-cell lung cancer	570	91 approved products
2	Metastatic cancer (cancer that has spread)	563	0 approved products
3	Small-cell lung cancer	366	15 approved products
4	Colorectal cancer	226	38 approved products
5	Prostate cancer	194	37 approved products
6	Pancreatic ductal adenocarcinoma	155	20 approved products
7	Ovarian cancer	153	24 approved products
8	Multiple myeloma	140	33 approved products
9	Melanoma	130	23 approved products
10	HR-positive / HER2-negative breast cancer	124	62 approved products
11	Head and neck squamous cell carcinoma	115	16 approved products
12	Non-Hodgkin lymphoma (all types)	109	0 approved products
13	Bladder & urothelial cancer	106	25 approved products
14	Gastric & gastro-oesophageal junction cancer	98	28 approved products
15	EGFR-mutated non-small-cell lung cancer	94	10 approved products
16	Hepatocellular carcinoma	91	18 approved products
17	HER2-positive breast cancer	90	18 approved products
18	Triple-negative breast cancer (TNBC)	90	24 approved products
19	Diffuse large B-cell lymphoma	81	35 approved products
20	Relapsed or refractory multiple myeloma	81	10 approved products
21	Metastatic castration-resistant prostate cancer	74	10 approved products
22	Glioma & glioblastoma	73	11 approved products
23	Endometrial cancer	72	9 approved products
24	Acute myeloid leukaemia	71	32 approved products
25	Renal cell carcinoma	67	19 approved products
26	Chronic lymphocytic leukaemia	65	22 approved products
27	Cervical cancer	63	15 approved products
28	Metastatic pancreatic ductal adenocarcinoma	62	2 approved products
29	Oesophageal cancer	54	7 approved products
30	Resectable stage I to III non-small-cell lung cancer	54	6 approved products
31	Biliary tract cancer (cholangiocarcinoma)	53	8 approved products
32	Hodgkin lymphoma	52	18 approved products
33	Acute lymphoblastic leukaemia	50	33 approved products
34	Advanced melanoma (unresectable stage III and stage IV)	49	12 approved products
35	Muscle-invasive and advanced bladder cancer	49	2 approved products
36	Sarcomas (soft tissue, bone, GIST)	47	22 approved products
37	Advanced hepatocellular carcinoma (BCLC C)	46	8 approved products
38	Follicular lymphoma	45	7 approved products
39	Extensive-stage small-cell lung cancer	43	8 approved products
40	Metastatic triple-negative breast cancer	38	6 approved products
41	Recurrent or metastatic head and neck squamous cell carcinoma	38	4 approved products
42	Brain and spinal cord tumours (all types)	37	0 approved products
43	Myeloproliferative neoplasms (PV, ET, myelofibrosis)	37	10 approved products
44	Non-muscle-invasive bladder cancer	34	3 approved products
45	KRAS G12C-mutant non-small-cell lung cancer	32	4 approved products
46	Mantle cell lymphoma	31	6 approved products
47	Myelodysplastic syndromes / neoplasms (MDS)	31	8 approved products
48	Platinum-resistant ovarian cancer	31	3 approved products
49	Neuroendocrine tumours	30	9 approved products
50	Childhood cancers (all types)	27	0 approved products

222 more cancers have a value below the top 50; the full list of cancers is at /cancers/.

How this is counted

Counts trial records whose cancers field lists the cancer. Trials that name several cancers count once for each. The context column counts products with status approved that list the cancer.

Coverage. 3,560 of 3,571 trials name at least one cancer (100%). Rows with a value of zero are not listed. Nothing is weighted, imputed or averaged; the ordering is by the number shown, then by name.

Machine-readable copy: /rankings/cancers-by-trials/data.json. Registry: src/lib/rankings.ts.

Cancers by number of trials

How this is counted

Other rankings